R Karmali1, E Kimby2, M Ghielmini3, I W Flinn4, L I Gordon5, E Zucca6. 1. Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA. Electronic address: reem.karmali@northwestern.edu. 2. Division of Hematology, Department of Medicine at Huddinge, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, Switzerland. 3. IOSI/Oncology Institute of Southern Switzerland, Bern, Switzerland; Group for Clinical Cancer Research, Bern, Switzerland; Swiss Group for Clinical Cancer Research SAKK, Bern, Switzerland. 4. Sarah Cannon Research Institute, Nashville, USA; Tennessee Oncology, PLLC, Nashville, USA. 5. Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA. 6. IOSI/Oncology Institute of Southern Switzerland, Bern, Switzerland; Swiss Group for Clinical Cancer Research SAKK, Bern, Switzerland; IELSG/International Extranodal Lymphoma Study Group, Bern, Switzerland.
Abstract
Background: With the introduction of the anti-CD20 antibody rituximab, the outcome of patients with follicular lymphoma (FL) has greatly improved over the last two decades. First-line prolonged rituximab monotherapy is effective, achieving long-term remission and prolonged failure-free survival in some patients. Additionally, rituximab has been shown to synergize with chemotherapeutic and novel targeted agents alike with measurable gains in duration of response. As such, rituximab has made its mark in the treatment of FL and remains a valid agent despite the availability of newer monoclonal antibodies. This review summarizes the evolving role of rituximab as the first available anti-CD20 monoclonal antibody, emphasizing its clear activity as a single agent and in combination with chemotherapy or molecular targeted agents, and setting the standard for the development of new anti-CD20 monoclonal antibodies. Conclusion: We provide data that support the ongoing use of rituximab as a therapeutic partner for novel agents in future clinical trials exploring chemotherapy-free alternatives.
Background: With the introduction of the anti-CD20 antibody rituximab, the outcome of patients with follicular lymphoma (FL) has greatly improved over the last two decades. First-line prolonged rituximab monotherapy is effective, achieving long-term remission and prolonged failure-free survival in some patients. Additionally, rituximab has been shown to synergize with chemotherapeutic and novel targeted agents alike with measurable gains in duration of response. As such, rituximab has made its mark in the treatment of FL and remains a valid agent despite the availability of newer monoclonal antibodies. This review summarizes the evolving role of rituximab as the first available anti-CD20 monoclonal antibody, emphasizing its clear activity as a single agent and in combination with chemotherapy or molecular targeted agents, and setting the standard for the development of new anti-CD20 monoclonal antibodies. Conclusion: We provide data that support the ongoing use of rituximab as a therapeutic partner for novel agents in future clinical trials exploring chemotherapy-free alternatives.
Authors: Alden A Moccia; Christian Taverna; Sämi Schär; Anna Vanazzi; Stéphanie Rondeau; Felicitas Hitz; Walter Mingrone; Thomas Pabst; Lidija Cevreska; Auro Del Giglio; Johann Raats; Daniel Rauch; Daniel A Vorobiof; Andreas Lohri; Céline Ruegsegger; Christine Biaggi Rudolf; Corinne Rusterholz; Stefanie Hayoz; Michele Ghielmini; Emanuele Zucca Journal: Blood Adv Date: 2020-12-08
Authors: Stuart W Hicks; Chiara Tarantelli; Alan Wilhem; Eugenio Gaudio; Min Li; Alberto J Arribas; Filippo Spriano; Roberta Bordone; Luciano Cascione; Katharine C Lai; Qifeng Qiu; Monica Taborelli; Davide Rossi; Georg Stussi; Emanuele Zucca; Anastasios Stathis; Callum M Sloss; Francesco Bertoni Journal: Haematologica Date: 2019-02-07 Impact factor: 9.941
Authors: Raja Shanker; Syed Ziauddin Ahmed Zaidi; Nawal Faiez AlShehry; Fahad AlGhmlas; Ibraheem Hussein Motabi; Shahid Iqbal; Ahmad Ali Butt; Hassan AlShehri; Imran Khan Tailor; Syed Yasir Altaf; Mubarak AlGhamdi; Mohammed Marie; Mansour AlFayez; Kamal Al Zahrani; Mohammed Dwaimah; Tahani Al-Halouli; Wafaa Al-Shakweer; Maied Zaher AlShehery; Abdul Rehman Zia Zaidi; Atta Munawar Gill; Belal Mohammed Albtoosh; Musab Ahmed Journal: JMIR Form Res Date: 2021-11-12
Authors: Joel Joelsson; Tove Wästerlid; Richard Rosenquist; Lasse Hjort Jakobsen; Tarec C El-Galaly; Karin E Smedby; Sandra Eloranta Journal: Blood Adv Date: 2022-04-26